23 November 2022 - The FDA has granted Eli Lilly’s long-acting insulin glargine biosimilar, Rezvoglar, an interchangeability designation, making it the second interchangeable insulin biosimilar in the US.
The FDA approved for Rezvoglar (insulin glargine-aglr), a biosimilar for Lantus (insulin glargine) that was originally approved in December 2021, for an interchangeability designation, allowing the product to be exchanged for the reference product at the pharmacy level without requiring physician permission.